Goldman Sachs Group Inc Rain Therapeutics Inc. Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 14, 2024	BUY	$0.82 - $1.42 $23,315 - $40,376	28,434 New	28,434 $24,000
Q3 2023 Nov 14, 2023	SELL	$0.82 - $1.42 $172,349 - $298,458	-210,182 Reduced 88.08%	28,434 $24,000
Q2 2023 May 14, 2024	BUY	$1.09 - $9.93 $167,352 - $1.52 Million	153,534 Added 180.45%	238,616 $286,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $167,352 - $1.52 Million	153,534 Added 180.45%	238,616 $286,000
Q1 2023 May 14, 2024	BUY	$7.77 - $12.47 $582,827 - $935,374	75,010 Added 744.74%	85,082 $743,000

Q1 2023 May 11, 2023	BUY	$7.77 - $12.47 $661,087 - $1.06 Million	85,082 New	85,082 $743,000
Q2 2022 May 14, 2024	BUY	$2.21 - $5.56 $22,259 - $56,000	10,072 New	10,072 $56,000
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $14,548 - $36,601	-6,583 Reduced 39.53%	10,072 $56,000
Q1 2022 May 16, 2022	BUY	$5.07 - $13.68 $33,548 - $90,520	6,617 Added 65.92%	16,655 $84,000
Q4 2021 Feb 14, 2022	BUY	$11.91 - $17.0 $119,552 - $170,646	10,038 New	10,038 $129,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.